Thymoma

This trial studies sacituzumab govitecan-hziy in adults with advanced thymoma and thymic carcinoma who have progressed after at least one prior treatment. The main goal is to find the overall response rate in these patients, which helps understand how the cancer responds to this therapy. The study is a Phase II trial led by Georgetown University focusing on this rare and advanced cancer type. Participants receive sacituzumab govitecan-hziy at a fixed dose of 10 mg/kg intravenously once weekly on Days 1 and 8 within 21-day cycles. Treatment continues until the cancer progresses or side effects become unacceptable. This approach allows ongoing monitoring of effects and tolerability over repeated cycles. During the study, participants will have regular blood tests, scans, and physical exams to track health and cancer status. Researchers will collect blood and tumor biopsies for research. They will measure outcomes like overall response rate at one year, duration of response, progression-free survival, and overall survival, with safety closely monitored throughout the treatment period.

Researchers are evaluating the combination of Adebrelimab with carboplatin or cisplatin plus etoposide chemotherapy and concurrent radiotherapy as a first treatment for patients with extensive-stage oligometastatic small cell lung cancer. This Phase II open-label study aims to assess the safety and effectiveness of this regimen in this patient group. The trial is led by Nanfang Hospital, Southern Medical University and focuses on patients with limited metastatic lesions and organs affected. Participants will first receive Adebrelimab intravenously along with carboplatin or cisplatin and etoposide for two cycles during the induction phase. Next, participants undergo concurrent chemoradiotherapy, including thoracic radiation and stereotactic body radiation therapy (SBRT) to metastases, combined with one to two cycles of chemotherapy. Following this, they will receive one to two additional cycles of Adebrelimab combined with chemotherapy, and then continue on Adebrelimab alone as maintenance therapy until disease progression, unacceptable side effects, or withdrawal from the study. During the study, participants will be closely monitored through clinical assessments, imaging, and laboratory tests to track progression-free survival and other measures such as overall survival and response rates, with follow-up lasting up to approximately 30 months. Safety will be monitored by recording adverse events throughout the treatment and maintenance phases. The total participation time includes induction, concurrent chemoradiotherapy, maintenance, and follow-up periods to fully evaluate treatment outcomes and tolerability.

Researchers are evaluating the Integrative Medicine at Home (IM@Home) program to see if it improves patient-reported values, outcomes, and experiences for people undergoing systemic cancer treatments such as chemotherapy, immunotherapy, radiotherapy, targeted agents, or cytoreductive surgery. This program is part of the IMPROVE research initiative and focuses on patients with various cancers including head and neck, thoracic, gynecologic, melanoma, breast, and ovarian cancers. The goal is to assess how virtual mind-body therapies may support cancer patients during their treatment journey. Participants will be randomly assigned to either the IM@Home group or an enhanced usual care group. Those in the IM@Home group will take part in a 12-week virtual program offering weekly synchronous mind-body and fitness classes via Zoom, led by trained therapists with oncology expertise. Classes include activities such as fitness, yoga, dance therapy, tai chi, meditation, guided meditation, and music therapy. Each session lasts 30 to 45 minutes, with time for feedback and discussion. The enhanced usual care group will receive standard care plus access to pre-recorded meditation and relaxation resources. During the 12 weeks, participants will be monitored through patient-reported assessments measuring fatigue severity, symptom intensity, insomnia, psychological distress, pain, treatment expectancy, satisfaction, and session attendance. Researchers will also track treatment disruptions and unplanned medical visits. These evaluations will help determine the impact of the IM@Home program on patient well-being and treatment experience throughout the study period.

Researchers are evaluating hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) to determine if it is a safe treatment option with minimal side effects for people with thymic malignancies that have spread to the lining of the lungs and chest. The study also aims to assess whether this radiation therapy is effective against cancer in these patients. This is a Phase II clinical trial sponsored by Memorial Sloan Kettering Cancer Center. Participants will receive radiation therapy over about 6 weeks, with a total dose of 50.4 Gy given in 28 sessions. There is an option for a higher dose to areas of visible remaining cancer while protecting normal tissues. This treatment targets the affected hemithoracic pleura, the lining of one side of the chest. During the study, participants will be monitored for side effects such as radiation pneumonitis over two years. Researchers will also measure progression-free survival at 12 months to see how well the cancer is controlled. Participants will have regular assessments including lung function tests and kidney function evaluations to ensure safety, with study participation lasting for at least two years of follow-up.

Researchers are evaluating the safety and effectiveness of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma, which are rare types of thoracic tumors. This phase II, open-label, single-arm study aims to address the urgent need for effective treatments in patients who have not benefited from first-line chemotherapy. Previous phase I studies showed promising results for KC1036, supporting further investigation. Participants will take 60 mg of KC1036 orally once daily in 21-day treatment cycles. Safety assessments will occur every 21 days, and tumor responses will be evaluated every two cycles. Treatment continues until the disease progresses, unacceptable side effects occur, or the patient chooses to stop. This multicenter study is sponsored by Beijing Konruns Pharmaceutical Co., Ltd. During the study, participants will undergo regular evaluations including tumor imaging to measure response and safety monitoring over approximately two years. Researchers will assess outcomes such as objective response rate, progression-free survival, disease control rate, duration of response, and adverse events. The study includes adults aged 18 to 75 with confirmed thymic tumors and measurable lesions, requiring ongoing monitoring throughout participation.

Researchers are evaluating the safety and effectiveness of different drug regimens in people with myasthenia gravis, a condition affecting muscle strength. The study aims to find the best treatment options that reduce side effects and improve quality of life. It uses a master protocol to test multiple treatments in separate groups called intervention-specific appendixes (ISAs). The platform study includes a common screening period and ISA-specific screening, treatment, and safety follow-up periods. One ISA focuses on adding empasiprubart intravenous infusion to efgartigimod intravenous infusion for participants with generalized myasthenia gravis who have a partial response to efgartigimod. Each ISA has its own schedule and duration. Participants will undergo screening, receive assigned treatments, and be monitored for safety and treatment effects over up to approximately seven years, depending on the ISA. Researchers will assess safety, tolerability, and how well the treatments work for different myasthenia gravis subtypes during the study periods.

Researchers are evaluating the safety and therapeutic relevance of empasiprubart as an add-on therapy to efgartigimod in people with AChR-Ab seropositive generalized myasthenia gravis who have a partial clinical response to efgartigimod. This study is part of the ADAPT Forward platform, aiming to identify the best treatments to reduce side effects and improve quality of life in myasthenia gravis. It is an exploratory Phase 2a study sponsored by argenx. The study includes a screening period followed by a run-in period (part A) where participants receive intravenous efgartigimod. Eligible participants then enter an add-on period (part B) receiving both efgartigimod and empasiprubart intravenously. Those not eligible for part B continue to a safety follow-up period (part C) receiving only efgartigimod. The total study duration for each participant is up to approximately 54 weeks. Participants will be monitored for adverse events and serious adverse events up to 21 weeks, focusing on safety and tolerability. Researchers will also assess changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, Quantitative Myasthenia Gravis (QMG) scores, and other clinical measures over the study periods. Safety follow-up continues for participants not entering the add-on phase, ensuring ongoing evaluation throughout the study.

Researchers are studying whether adding radiotherapy after complete surgical removal improves survival in patients with stage II or III thymoma. This study aims to clarify the benefit of adjuvant radiotherapy since previous research shows better outcomes with complete resection but the role of additional radiotherapy remains unclear. The trial is sponsored by Fudan University and focuses on patients with this specific type and stage of thymoma. Participants are randomly assigned to one of two groups: one group receives adjuvant radiotherapy delivering a total of 50Gy divided into 25 sessions after their complete tumor removal, while the other group undergoes complete resection alone without further treatment. This open-label, multi-center trial compares these approaches to assess their impact on survival. Throughout the study, participants will be monitored for disease-free survival over five years as the main outcome. Secondary measures include overall survival and tracking any treatment-related side effects using standard criteria. Patients will undergo regular follow-ups and evaluations to assess their health status and treatment effects during this period, which lasts up to five years after enrollment.

This research focuses on children and adolescents with very rare tumors that occur at an annual rate of less than two per million children. These tumors include a wide variety of cancers, some rarely seen at any age and others more typical in adults but rare in pediatric patients. The study aims to gather detailed data to better understand these tumors and how their clinical and biological traits influence treatment outcomes, addressing the current lack of unified diagnostic criteria and information. The study is an international, prospective observational study supported by Padua University Hospital AOUP and the European Reference Network for Paediatric Oncology. It collects epidemiological, clinical, biological, radiological, and treatment data without proposing specific treatments. Collaboration across various European centers allows for comprehensive data collection to improve future diagnosis and treatment recommendations. Participants will be children and adolescents between birth and 18 years old diagnosed or treated for very rare tumors at participating centers. Researchers will collect and analyze data on epidemiology, adherence to international recommendations, and survival outcomes over about one year. The study involves no intervention but monitors participants' clinical progress through data gathering to enhance knowledge and care for rare pediatric cancers.

Researchers are evaluating a new treatment called TNhYP218 CAR T cells for people with solid tumors, including mesothelioma, which is a fast-growing cancer affecting the linings of organs such as the lungs and heart. This treatment uses a person's own immune cells, which are modified in a lab to better target and attack tumor cells that have high levels of a protein called mesothelin. The study is a phase 1 trial aiming to find the right dose and observe early responses in participants with mesothelioma and other tumors expressing mesothelin. Participants will have their tumor tissue tested for mesothelin levels through a biopsy. Blood is collected to isolate T cells, which are then genetically changed to create TNhYP218 CAR T cells. Before receiving the modified cells, participants undergo chemotherapy to prepare the body. The TNhYP218 CAR T cells are given through a vein, and patients stay in the hospital for about two weeks during treatment and initial monitoring. The study includes a dose escalation phase and a dose expansion phase for mesothelioma patients at the recommended dose. During the study, participants will have regular follow-up visits for up to 5 years, including imaging scans, blood tests, heart exams, and possible additional biopsies to monitor response and safety. Long-term monitoring for an additional 10 years will assess ongoing safety and treatment effects. The main goals are to find a safe dose, evaluate early tumor response by imaging, and track side effects and overall health over time.